Cancer
-
March 5, 2024
GE HealthCare & Vanderbilt publish data on AI models predicting patient response to immunotherapy
The results from a research partnership between GE HealthCare and Vanderbilt University Medical Center utilizing artificial intelligence to enable safer and more precise cancer immunotherapies show that the models they developed predict patient responses with 70% to 80% accuracy. -
March 1, 2024
Study seeks to determine if fallopian tube sonograms can help detect ovarian cancer at early stage
Vanderbilt researchers are investigating whether sonograms of fallopian tubes can be effective for the early detection of ovarian cancer, and their ongoing study shows promise. -
February 27, 2024
Multi-institutional study of Wilms tumor facilitates enrollment, optimizes treatment
Multi-institutional study finds that enrollment and outcomes were similar across various groups of children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide. -
February 16, 2024
Waddell Walker Hancock Cancer Discovery Fund names first scholars
A research endeavor that seeks to develop a new cancer immunotherapy utilizing nanobody delivery and targeted heating of tumors has received funding from the Waddell Walker Hancock Cancer Discovery Fund. -
February 7, 2024
Vanderbilt nanodrug may be a paradigm shift for cancer
A multidisciplinary research team at Vanderbilt University and Vanderbilt University Medical Center has discovered a new way to kill a tumor by disrupting its acidic “microenvironment” without harming normal tissue. -
January 31, 2024
Fatty acids rewire energy supply chain in stomach cancer development
A study by Vanderbilt researchers has revealed how metabolic changes spurred by fatty acids contribute to the transformation of cells into abnormal versions of themselves that are the precursors to stomach cancer. -
January 24, 2024
Long-term follow-up pinpoints side effects of treatments for prostate cancer patients
A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population.